LBL 2018 and B-NHL 2013: 
therapy optimisation trials for the treatment of non-Hodgkin lymphomas 

Non-Hodgkin lymphomas (NHL) are the fourth most common childhood cancer. They cover a variety of malignant diseases of the lymphatic system in which certain white blood cells, called lymphocytes, turn into cancer cells and no longer perform their tasks in the immune system. Without treatment, these malignant cells will grow unhindered, leading to a life-threatening situation. 

Aims of the trials
LBL 2018 and B-NHL 2013

The LBL 2018 trial aims to improve recovery rates and prevent the occurrence of relapses – especially in the brain and spinal cord. The aim of the B-NHL 2013 trial is to reduce side effects and long-term consequences of therapy in patients with a relatively unadvanced stage of the disease thanks to the additional administration of the drug rituximab in the treatment of some forms of non-Hodgkin lymphomas. Furthermore, it aims to improve the overall recovery rates for patients with (slightly) more advanced stages of the disease. In addition, the trial aims to promote a better understanding of the biology of the disease and the mechanisms of disease development in order to develop new drugs, therapeutic approaches and diagnostic methods.

Implementing organisation

Swiss Paediatric Oncology Group (SPOG)